SR

Sridhar Ramaswamy

Physician

Boston, Massachusetts

Invests in

Stages:

  • Min Investment:

    $250,000.00
  • Max Investment:

    $50,000,000.00
  • Target Investment:

    $25,000,000.00

Work Experience

2019

  • Venture Partner

    2021

    Investing in early-stage life science companies • Leyden Labs, Board Observer (2021-present) • Invetx, Board Observer (2022-24 / M&A 2024) • Invivyd, Board Observer (2020-21 / IPO 2021)

  • Entrepreneur In Residence

    2019

    Biotech company creation • Q1, Inc., Founder & CEO (2020-present) • Q2, Inc., Founder & CEO (2023-present)

  • Guest Lecturer

    2019

    • Massachusetts Institute of Technology • Broad Institute of Harvard & MIT • Harvard Business School

  • Scientific Advisory Board

    2018

2016 - 2019

  • Senior Vice President & Head, R&D

    2016 - 2019

    Research & Development, Cancer Therapeutics, Executive Leadership • Built and led a matrix team of 70 drug discovery, translational, and development experts that worked closely with BD, CMC, medical, regulatory, and commercial strategy groups to enable the integrated and externalized discovery, development, and commercialization of a cancer and immuno-oncology pipeline • Directed early pipeline creation through discovery, acquisition, and partnership; early development of new therapeutics from concept through first-in-man studies; and translational science to best position our drugs at the right dose, schedule, and cancer indications so patients most likely benefit • Contributed to small-molecule and antibody discovery, early development, translational biomarker identification & strategy, clinical development & regulatory approval, and commercialization of 11 cancer drugs including niraparib (PARP1/2), dostarlimab (PD1), cobolimab (TIM3), and rolapitant (NK1) for patients with ovarian, prostate, uterine, rectal and other solid tumors • Represented R&D externally with the scientific, medical, regulatory, commercial, and investor communities • Served as a key member of the executive leadership team that led TESARO as a publicly traded, oncology-focused, global biopharmaceutical company and spearheaded its successful acquisition and integration by GSK for $5.1B

  • Associate Professor of Medicine

    2001 - 2019

    Medical Oncology & Hematology, Translational & Basic Research, Teaching & Administration • Directed the highly-specialized, multidisciplinary care for patients with breast, GI, and hematologic cancers in both the inpatient and outpatient settings at the Massachusetts General Hospital, Brigham & Women's Hospital, and Dana-Farber Cancer Institute • Founded and directed a highly-influential, NIH-funded, multidisciplinary research program focused on understanding how human carcinomas grow and progress from localized cancers, via circulating tumors cells, into advanced, metastatic, dormant, and treatment-resistant disease (h-index = 73) • Developed cancer systems biology approaches to study human tumors as complex, adaptive, multi-scale systems • Disseminated many tools, methods, and approaches invented by my research group to the worldwide cancer research, translational medicine, and drug development communities • Taught a generation of medical & graduate students, interns & residents, and clinical & research fellows in the classroom, at the bench, and the bedside.

  • MGH / Samana Cay Endowed Investigator

    2015 - 2017

    Cancer Biology & Therapeutics, Translational & Basic Research, Teaching, Administration

  • Director, Center for Computational Biology

    2004 - 2017

    Integrative, Systems, & Computational Biology, Bioinformatics, Data Science

  • Tucker Gosnell Investigator

    2004 - 2017

    Medical Oncology, Cancer Biology & Therapeutics, Translational & Basic Research, Teaching, Administration

  • Principal Investigator, Center for Cancer Research

    2004 - 2017

    Patient-oriented laboratory research

  • Attending Physician in Medicine & Cancer Center

    2000 - 2017

    Medical Oncology, Hematology, Internal Medicine

  • Associate Member

    2006 - 2017

    Genetics & Genomics, Systems Biology, Data Science

  • Principal Member

    2006 - 2017

    Stem Cell Biology, Regenerative Medicine

  • Associate Member

    2006 - 2017

    Cancer Biology, Cancer Therapeutics & Diagnostics

  • Attending Physician in Medicine

    2001 - 2004

    Medical Oncology, Therapeutics, & Diagnostics, Translational & Basic Research, Cancer Biology, Teaching

  • Attending Physician in Medicine

    2001 - 2004

    Medical Oncology, Therapeutics, & Diagnostics, Translational & Basic Research, Cancer Biology, Teaching